🇪🇺 Fast delivery (3–5 working days) with GLS ✅ Card or bank transfer 📦 Free shipping from €50
Cagrilintide 101: how the amylin agonist works and the combination with semaglutide
cagrilintide is a long-acting amylin agonist (sometimes referred to as an „amylin analogue“). Amylin is a hormone co-secreted with insulin by pancreatic beta cells and plays a key role in regulating satiety, delaying gastric emptying and suppressing glucagon . In people with overweight and/or type 2 diabetes an amylin deficiency or resistance has been described, which is one factor contributing to increased appetite and „food noise“. The idea behind cagrilintide is to restore that signal to the brain and gastrointestinal tract on a predictable, weekly schedule .
Cagrilintide 101: how the amylin agonist works and the combination with semaglutide
Peptology · 2026-06-04
What is cagrilintide?
cagrilintide is a long-acting amylin agonist (sometimes referred to as an „amylin analogue“). Amylin is a hormone co-secreted with insulin by pancreatic beta cells and plays a key role in regulating satiety, delaying gastric emptying and suppressing glucagon. In people with overweight and/or type 2 diabetes an amylin deficiency or resistance has been described, which is one factor contributing to increased appetite and „food noise“. The idea behind cagrilintide is to restore that signal to the brain and gastrointestinal tract on a predictable, weekly schedule.
At the molecular level cagrilintide acts via the amylin receptors (AMY) — heterodimeric complexes between the calcitonin receptor (CTR) and the so-called RAMPs (receptor activity-modifying proteins 1–3). This „two-component“ architecture explains why different agonists (amylin, calcitonin, and synthetic analogues) can have different selectivity and effect. New structure-dynamics studies show that cagrilintide binds in an amylin-like manner but induces specific conformational changes in the CTR+RAMP complex, which likely contributes to its clinical efficacy.
Mechanism of action: „satiety axes“ beyond GLP-1
cagrilintide modulates several key processes:
-
Increases satiety and reduces hyperphagia. The amylin signal in brain appetite centres leads to lower spontaneous caloric intake and a „quiet mind“ regarding food.
-
Delays gastric emptying. Slower gastric transit prolongs the feeling of fullness after a meal.
-
Modulates hormones of glucose homeostasis. Postprandial suppression of glucagon contributes to more stable postprandial glycaemia.
Importantly, the amylin axis is distinct from GLP-1, although the effects „meet“ on appetite and gastrointestinal motility. It is precisely the complementarity that underlies interest in combining cagrilintide with semaglutide (a GLP-1 agonist), to achieve a deeper and more durable weight reduction.
Pharmacokinetics: designed for once-weekly administration
In an early human trial cagrilintide showed a long half-life ~159–195 hours (6.5–8 days) and tmax 24–72 hours, with a profile that supports weekly dosing — similar to semaglutide (GLP-1) in convenience, but via a different biological axis. This is important for adherence and real-world effectiveness in practice.
What do the clinical data show for cagrilintide as monotherapy?
The first larger published trial in people with overweight/obesity (without diabetes) showed that once-weekly cagrilintide leads to a clinically significant, dose-dependent weight reduction over 26 weeks, with the highest doses reaching ~10.8% versus baseline weight (by the „trial product estimand“), outperforming placebo. The most frequent adverse events were the GI effects expected for the class (nausea, vomiting, diarrhoea) — mostly mild to moderate.
This put cagrilintide on the map as a highly promising amylin agonist, capable on its own of achieving results similar to some published effects of GLP-1 therapies, but via a different mechanism — which is why it is also studied as a combination partner.
Why is the combination with semaglutide (CS10) attracting so much attention?
When the two satiety axes — GLP-1 (semaglutide) and amylin (cagrilintide) — are combined, effects on appetite, gastric transit and energy intake are potentiated. This was demonstrated in a randomised phase 2 study, where the co-administration led to a greater weight reduction than either agent alone.
In June 2025 phase 3a data from the REDEFINE programme were published — with parallel publications in NEJM and presentations at ADA. In summary: the cagrilintide + semaglutide combination leads to a significantly greater weight reduction versus placebo and versus each agent alone, both in people without diabetes (REDEFINE-1) and in people with T2D (REDEFINE-2). Different reports and subanalyses cite mean reductions around 20–23% at 68 weeks in the non-diabetic population, and in T2D a double-digit reduction exceeding controls.
Context: Numbers vary according to statistical method, populations and adherence analysis — so it is correct to speak of ranges, not a single "magic" number. Nevertheless the consistent signal is clear: the two mechanisms together achieve a greater mean reduction.
Safety and tolerability: what to expect from published data
As with GLP-1s, the most common adverse events with cagrilintide and with the combination are gastrointestinal (nausea, vomiting, diarrhoea, constipation), usually mild to moderate and transient. In the combination trials (including REDEFINE) the safety profile is described as consistent with known class effects, without new key signals. Of course, full assessment requires official label documents and post-marketing surveillance.
Important (YMYL): This text is educational and does not provide medical advice. Decisions on diagnosis, treatment, dosing and combining therapies must be made only by a medical professional, according to the official product information.
Where does cagrilintide fit in the „new wave“ of weight therapies?
After the strong results from GLP-1 and GLP-1/GIP agonists (semaglutide, tirzepatide), interest turned to new hormonal „axes“ and combinations: amylin mimetics (such as cagrilintide), triagonists (e.g. retatrutide) and multimodal molecules. In this landscape cagrilintide is mechanistically distinct, and in combination with semaglutide (CS10) shows weight reductions that in some analyses approach or exceed some published values for other classes — an important signal that complementary hormones may be the path to more complete and durable efficacy.
TLDR
-
Different biology, similar convenience. Cagrilintide is once weekly, with a long half-life, similar to semaglutide — but works via the amylin receptors, not via GLP-1.
-
Solo and team player. As monotherapy it shows significant weight loss over 26 weeks; in combination with semaglutide — an even greater mean reduction in longer trials (68 weeks).
-
Responses vary. As with GLP-1, individual response varies in trials, and the weight curve flattens over time („plateau“). After treatment is stopped, part of the lost weight is usually regained — as described for behavioural and pharmacological weight interventions in general and shown for GLP-1s in individual trials.
-
Safety and labelling. Real-world use, indications, contraindications and risks depend on the official product information and clinical judgement.
Frequently Asked Questions (FAQ)
What is cagrilintide (cagrilintide)?
A long-acting amylin agonist for once-weekly administration; enhances satiety, delays gastric emptying and supports weight reduction via the amylin receptors (CTR+RAMP).
How does it differ from semaglutide?
Semaglutide is a GLP-1 agonist; cagrilintide targets the amylin receptors. The two mechanisms are complementary.
What results have studies shown?
As monotherapy: up to about ~10.8% mean at 26 weeks; in combination with semaglutide: ~20–23% mean at 68 weeks in non-diabetic populations; in T2D — double-digit reductions with superiority versus control arms. Numbers vary by analysis and population.
What are the most common side effects?
Primarily GI-related (nausea, vomiting, diarrhoea/constipation), most often mild to moderate — similar to GLP-1 classes. Details depend on the official label.